Medicine
Leqvio 284 mg/1.5 mL injection
Leqvio 284 mg/1.5 mL injection is a prescription medicine containing Inclisiran for subcutaneous use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store LEQVIO at controlled room temperature 20°C to 25°C (68°F to 77°F) with…
Key facts
- Active ingredient (INN)
- Inclisiran
- Brand
- Leqvio
- Strength
- 284 mg/1.5 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 1.5 mL
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store LEQVIO at controlled room temperature 20°C to 25°C (68°F to 77°F) with allowable excursions between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C10AX16 Inclisiran
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 December 2021
- Identifiers
- RxCUI 2588263, 2588269DailyMed set ID 6fc0afca-4513-4c35-b594-6544aee29a44NDC 0078-1000Application NDA214012
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / 1.5 mL in 1 syringe, glass | 0078-1000-60 | Novartis Pharmaceuticals | 22 December 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Inclisiran is a prescription medicine indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. It is available as injection for subcutaneous use. MedsAcross supplies Inclisiran for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about InclisiranFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LEQVIO prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Leqvio: European public assessment report (EPAR) · European Medicines Agency
Need Leqvio 284 mg/1.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.